Table 1.

Clinical data of the asthma PreDicta cohort WP1-UK-ER analyzed at the baseline visit.

Patient ID	Age at B0 [years]	Gender	Asthma severity (GINA 2005)	Asthma control (GINA 2009)	Treatment	PBMC SN PHA IL3 [pg/ml]
A1	6	Male	I	Controlled	Steroid	152,182
A2	6	Male	II	Partially controlled	Steroid	75,870
A3	5	Female	II	Partially controlled	Steroid	22,678
A4	6	Male	II	Controlled	Steroid	48,344
A5	5	Male	I	Partially controlled	Steroid	25,122
A6	5	Female	I	Controlled	Steroid	51,480
A7	5	Male	I	Partially controlled	Steroid	58,026
A9	4	Female	n.a.	Partially controlled	Steroid	n.m.
A10	6	Female	I	Partially controlled	Non-steroid	n.m.
A12	5	Male	II	Controlled	Steroid	n.m.
A13	4	Male	III	Partially controlled	Steroid	38,544
A16	5	Female	III	Uncontrolled	Steroid	6,436
A17	6	Female	I	Uncontrolled	Steroid	0,000
A23	5	Male	I	Controlled	Steroid	14,320
A24	4	Female	I	Controlled	Steroid	64,980
A25	4	Male	I	Controlled	Steroid	0,000
A28	5	Male	I	Controlled	Non-steroid	0,000
A29	4	Male	I	Controlled	Non-steroid	5,082
A30	5	Male	I	Controlled	Non-steroid	0,000
A31	4	Male	I	Partially controlled	Steroid	0,000
A38	4	Male	I	Controlled	Steroid	50,610
A39	5	Female	I	Controlled	Non-steroid	0,000
A42	5	Male	II	Controlled	Steroid	0,000
A43	5	Female	II	Uncontrolled	Steroid	0,000

Asthma severity: I = intermittent: FEV1 > 80%; MEF > 65%; symptom-free interval > 2 months. II = mild persistent: FEV1 > 80%; MEF > 65%; symptom-free Interval < 2 months. III = moderate persistent: FEV1 < 80%; MEF < 65%; symptoms several days a week. IV = severe persistent: FEV1 < 60%; symptoms during the day and night.

FEV1, forced expiratory volume in 1 s; MEF, maximal expiratory flow; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin.